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Identification of Multiple Complex Rearrangements
Associated with Deletions in the 6q23-27 Region in
Se´zary Syndrome
Katarzyna Iz˙ykowska1, Mariola Zawada1, Karina Nowicka1, Piotr Grabarczyk2, Floriane C.M. Braun2,
Martin Delin2, Markus Mo¨bs3, Marc Beyer3, Wolfram Sterry3, Christian A. Schmidt2 and Grzegorz K. Przybylski1,2
The 6q23-27 region, recurrently deleted in Se´zary syndrome (SS), was characterized at the molecular level in 13 SS
patients and SS cell line SeAx. Using fine-tiling comparative genomic hybridization, deletions within the 6q23-27
region were detected in half of the samples (six patients and SeAx). All samples with deletions were further
analyzed by ligation-mediated PCR. In addition, in one patient sample and in SeAx, paired-end next-generation
sequencing was performed on the HiSeq2000 Illumina platform. Using those techniques, 23 rearrangements
associated with the deletions were identified. The majority of rearrangements showed enormous complexity and
diversity, including eight inversions, three transpositions, and four translocations (with chromosomes 3, 17, 10,
and 12). Fifteen genes were disrupted by those rearrangements, the MYB proto-oncogene three times and the
interleukin-22 receptor subunit alpha-2 gene (IL22RA2) twice. All three patients with MYB alterations showed low
MYB expression, whereas seven of the remaining patients showed overexpression. Most patients overexpressing
MYB also presented increased expression of MYC, HSPA8, and BCL2. Five gene fusions were identified, of which
two, CCDC28A–IL22RA2 and AIG1–GOSR1, both in SeAx, were in the same orientation and were expressed at the
messenger RNA level.
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INTRODUCTION
Se´zary syndrome (SS) is a rare form of cutaneous T-cell
lymphoma (CTCL) characterized by erythroderma and the
presence of Se´zary cells (CD3þ , CD4þ , and CD8 ) in skin,
lymph nodes, and peripheral blood (Hwang et al., 2008). The
etiology and molecular pathogenesis of SS are poorly known.
The disease remains fatal, with a median survival between
2 and 4 years, and limited therapeutic options (Prince et al.,
2009). Chromosomal instability is characteristic of this lym-
phoma and related to bad prognosis (Caprini et al., 2009), but
only few specific abnormalities that may be directly involved
in the development of the disease have been found so far.
Over the past few decades, cytogenetic and molecular
cytogenetic findings revealed many genetic alterations in
patients with SS. Recurrent regional gains are usually
observed at 17q, 8q, and 17p, whereas regional losses were
observed at 17p, 10q, 6q, 9q, 10p, 9p, and 19p (Izykowska
and Przybylski, 2011; Steininger et al., 2011). The 6q region
caught our attention because it is recurrently deleted in SS
(Espinet et al., 2004; Batista et al., 2006) and correlated to
poorer prognosis in CTCL (Fischer et al., 2004). It is also recur-
rently altered in different cancer types, and thus might carry
genes important in oncogenesis (Taborelli et al., 2006).
Using high-resolution fine-tiling comparative genomic
hybridization (FT-CGH) array, we found deletions in the
6q23-27 region in 6 out of 13 SS patients and in the SS-
derived cell line SeAx (Braun et al., 2011). The common
region in those deletions contained the tumor necrosis factor
alpha–induced protein 3 (TNFAIP3; A20), which is a putative
tumor suppressor in CTCL. Besides deletion of the A20-
encoding gene (TNFAIP3), FT-CGH revealed many different
breakpoints, which we decided to further analyze at the
molecular level. Our previous studies showed that copy
number changes, detected by array comparative genomic
hybridization, might be associated with small structural
aberrations such as inversions or translocations (Przybylski
et al., 2010). Detailed molecular characterization of DNA
changes has the potential to reveal genes being deregulated
and possible gene fusions (Przybylski et al., 2005). To
sequence each breakpoint and identify possible rearrange-
ments, samples with deletions were analyzed by ligation-
mediated PCR (LM-PCR). In addition, the SeAx cell line was
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analyzed by fluorescence in situ hybridization (FISH) with
painting probes, and in two samples paired-end next-generation
sequencing (NGS) was performed on the HiSeq2000 Illumina
platform. The number of identified rearrangements and their
complexity were even higher than expected based on the
results of FT-CGH.
RESULTS AND DISCUSSION
Complex rearrangement pattern revealed by combining FT-CGH
with LM-PCR
The main limitation of array comparative genomic hybridiza-
tion is that it does not detect structural aberrations, which
might be associated with deletions. Combining FT-CGH with
LM-PCR allows to overcome this problem. Using LM-PCR
with primers specific for 6q23-27, located at the borders of the
deletions visible in FT-CGH, 33 breakpoints (24 in five SS
patients and 9 in SeAx) were amplified and sequenced. In one
SS patient (249), no rearrangement could be amplified owing
to the presence of a single large deletion, with its border
located outside of the region covered by the FT-CGH array.
Using this approach, 19 rearrangements were identified,
including 7 deletions, 6 inversions, 3 translocations (with
chromosomes 3, 10, and 12), and 3 transpositions. As a result
of those rearrangements, 11 genes were disrupted on chromo-
some 6 (MAP7, BCLAF1, PDE7B, SMOC2, IL22RA2, SYNE1,
CCDC28A, AIG1, PERP, REPS1, and MYB). Five rearrange-
ments were associated with short insertions (27–1,623bp);
in one case, the insertion was originated from a different
chromosome (chr19). All rearrangements associated with
deletions in the 6q23-27 region in SS samples are presented
in Supplementary information 1 online and the nucleotide
sequences in Supplementary information 2 online (GenBank
accession numbers KC009655–9679). One FT-CGH/LM-PCR
analysis is presented as an example in Figure 1.
Rearrangements identified by combining FT-CGH and
paired-end next-generation sequencing
Recently, NGS has been used for the identification of genomic
rearrangements (Chen et al., 2008, 2010; Feldman et al.,
2011; Grossmann et al., 2011; Sobreira et al., 2011; Talkowski
et al., 2011). In this project, one SS patient (312) and SeAx
cell line were additionally analyzed using NGS; besides
confirmation of rearrangements previously identified by
LM-PCR, four additional rearrangements were found. In patient
312, breakpoints in the 6q23-27 region were analyzed by
PE NGS using the IGV2.1 software instead of LM-PCR.
Two rearrangements of inverted DNA fragments (15 and 16;
Supplementary information 1 online), associated with four
breaks seen in FT-CGH, were identified. The most likely
explanation of those rearrangements is an inversion of
a 164,252-bp DNA fragment, associated with a large
15,024,515-bp proximal and a small 9,496-bp distal deletion
(Figure 2). As a result, the iodotyrosine deiodinase gene (IYD)
was split; the major part (exons 1–4) was fused head to head
with MYB proto-oncogene (exons 1–14), exon 5 and the
majority of exon 6 were deleted, and a small part of the 3’
UTR of exon 6 was fused tail to tail with the last (fourth) exon
of the protein phosphatase 1, regulatory subunit 14C gene
(PPP1R14C). As none of the gene fusions was in right
orientation, no fusion transcript was expected.
In SeAx, LM-PCR was performed first, and subsequently all
five identified rearrangements were confirmed by NGS
(Figure 3; Supplementary information 1 online). In addition,
NGS revealed a more complex nature of the rearrangement,
22 identified by LM-PCR, including inversion of 6q combined
with a 270-bp insertion from the third intron of the solute
carrier family gene SLC27A5 located at 19q13.43. Moreover,
a detailed analysis of the breakpoint at chr6:143,501,752,
associated with translocation t(3;6), led us to identify an
additional translocation between the region located just
231bp proximally from that break and a fragment of chromo-
some 17. Most likely, the long arm of the chromosome was
broken, the proximal part of chr6 was translocated to chr17,
the distal part of chr6 was translocated to chr3, and the short
231-bp fragment was deleted during this rearrangement. The
t(6;17) fused, in the same orientation, the androgen-induced
1 gene (AIG1) and the Golgi SNAP receptor complex member
1 gene GOSR1 (Figure 4).
A limitation of LM-PCR is its range of 3–4kb, which does
not allow amplification of long tandem repeats with no
restriction sites. Therefore, not all breaks visible in FT-CGH
could be amplified. One such breakpoint, associated with
telomere repeats (TTAGGG), was clarified by NGS in SeAx.
The process called ‘‘telomere healing’’ is related to the
stabilization of terminal deletions by the direct addition of
telomeric repeats onto the end of a broken chromosome
(Varley et al., 2000; Ballif et al., 2004). Deficiency in
chromosome healing in human cancer cells increases the
frequency of chromosome rearrangements leading to tumor
cell progression.
To sum up, results of FT-CGH and LM-PCR are concurrent
with paired-end NGS, but the latter method has the advantage
of detecting balanced aberrations as well. Both approaches
can identify even very small genetic alterations and reveal a
direct position of each breakpoint. In our opinion, the
techniques we used are too time- and labor-consuming to
be currently used in clinical practice. We recommend using
those techniques to get a complete picture of the genetic
lesions. Once recurrent and relevant rearrangements are
described, a simple PCR or array-based approach for clinical
use can be developed.
Cytogenetic confirmation of rearrangements detected in the
SeAx cell line
Most of the rearrangements identified by LM-PCR within
6q23-27 are too small to be detected by cytogenetics. To
check whether the chromosomal translocations are present at
the microscopic level, karyotyping and FISH analysis were
performed in the SeAx cell line. Two whole chromosome
painting probes for chromosomes 6 and 3 were used in order
to visualize t(3;6) in SeAx. At least 30 metaphase cells were
analyzed, and two fusions between chromosomes 6 and 3
were detected in all of them: der(3)t(3;6) and der(3)t(3;6;?)
(Figure 5a). As the latter chromosome contained unstained
material from other chromosomes, multicolor FISH (mFISH)
analysis was performed in order to explain this complex
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aberration. In addition to the two t(3;6), fusions between
chromosomes 6 and 17 and chromosomes 3 and 17 were
identified (Figure 5b). In general, mFISH analysis confirmed
the presence of rearrangements between chromosomes 6 and
3, and also between chromosomes 6 and 17 in the SeAx cell
line. However, many positions were indicated by a question
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Figure 1. Complex rearrangements identified by combining fine-tiling comparative genomic hybridization (FT-CGH) and ligation-mediated PCR (LM-PCR).
Three different rearrangements, transposition, deletion, and inversion, all involving a duplicated 1,064-kb region, were identified in Se´zary syndrome (SS) patient 247.
In the picture, the inversion identified by LM-PCR is presented (rearrangement nr 14, amplified with primers 148,702,669f and 148,702,771f). This inversion and the
deletion disrupted the MYB gene, localized at the distal end of the duplicated region. C, control sample; G, germ-line configuration; M, size marker; R, rearrangement.
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Figure 2. Combination of fine-tiling comparative genomic hybridization (FT-CGH) and paired-end next-generation sequencing (NGS) for identification of
rearrangements in the 6q23-27 region in Se´zary syndrome (SS) patient 312. Region 150.5–150.8M was enlarged to indicate the inverted 164,252-bp DNA
fragment and gene fusions that arose as a result of this rearrangement. IYD, iodotyrosine deiodinase gene.
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mark because of the uncertainty in band designation. To align
the mFISH results with the molecular data, NGS results
were searched for rearrangements among chromosomes
6, 3, and 17. The sandwich chromosome der(3)t(3;6;17;9)
(Figure 5c) was in line with three rearrangements detected
by NGS: one (20) in the studied region, 6q24.2 (143,502 k)
þ :þ17q11.2 (25,830 k), and two additional rearrange-
ments, (24) 3q26.1 (167,021 k)-:þ 6q21 (106,549 k) and
(25) 3q13.2 (113,776 k)þ :-3q26.1 (167,027 k), outside of the
studied region (Supplementary information 1 online). Those
rearrangements were confirmed by PCR on genomic DNA,
including amplification spanning the 5,798-bp inverted
DNA fragment derived from chr3q26.1 (167,027,014-
167,021,217), inserted between the chromosomes 3 and 6.
Our data indicate that the cytogenetic and molecular
analyses of the cancer genome, although providing different
information, are compatible. As shown for SeAx, rearrange-
ments between two chromosomes can be confirmed by
chromosome painting. In addition, the other way round, for
the complex ‘‘sandwich chromosome’’ seen in multicolor
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Figure 3. 6q23-27 rearrangements in Se´zary syndrome cell line (SeAx) cell line identified by fine-tiling comparative genomic hybridization (FT-CGH) and
next-generation sequencing. (a) FT-CGH analysis showed deletions in the 6q23-27 region in SeAx; breakpoints were characterized using ligation-mediated
PCR (LM-PCR), and five rearrangements were identified; all rearrangements were confirmed using paired-end sequencing, and one breakpoint was identified
to be associated with telomere repeats; two gene fusions were identified at the DNA level, yet only IL22RA2/CCDC28A fusion had the orientation to create a
possible transcript. (b) Two inversions in SeAx cell line identified by FT-CGH/LM-PCR and paired-end sequencing; biallelic deletions visualized with both
techniques.
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FISH, resulting from a fusion of chromosomes 3, 6, 17, and 9,
matching DNA rearrangements could be found.
Expression of genes disrupted in SS
Genes with altered expression due to genomic imbalances, as
well as gene fusions, might be used in the future as targets for
very specific and effective therapies (Mitelman et al., 2007;
Sellers, 2011).
In our study, including only seven samples, as a result of
identified rearrangements, 15 genes were directly disrupted.
Two of them, the proto-oncogene MYB and interleukin-22
receptor subunit alpha-2 gene (IL22RA2), were affected more
than once. In three rearrangements, breakpoints were inside
the MYB gene, which encodes a transcription factor, and is
often rearranged and overexpressed in cancer, including CTCL
(Qin et al., 2001; Poenitz et al., 2005; Stenman et al., 2010).
To study the consequences of gene disruption at the
messenger RNA (mRNA) level, expression of three directly
affected genes, MYB, IL22RA2, and PERP, and three genes
known to be involved in the C-MYB transcription factor
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network, MYC, BCL2, and HSPA8, were analyzed in all SS
patients by real-time quantitative PCR (RQ-PCR) with specific
TaqMan probes (Figure 6).
To check whether the loss of MYB 30 UTR, involved in
negative regulation of MYB expression by microRNAs (Persson
et al., 2009), resulted in overexpression of the shortened
transcript, RQ-PCR for the 50 end of MYB (exons 1–2)
and for the 30 end of MYB (exons 14–15) was performed.
Despite predictions, in samples 247 and 312, no difference
between expression of the 50 and the 30 end was observed,
suggesting that deletions of 30 UTR did not result in increased
expression of this gene (Figure 6). Those results were con-
firmed by comparative PCR with two different primer sets for
the 50 and 30 end of MYB (data not shown). In concordance
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Figure 6. Quantitative expression analysis of genes disrupted by a rearrangement. Expression of three genes (MYB, PERP, and IL22RA2) directly affected
by a rearrangement and three genes (MYC, HSPA8, and BCL2) regulated by MYB was analyzed using real-time quantitative PCR with specific TaqMan probes
in six Se´zary syndrome (SS) patients with and seven SS patients without 6q23-27 alterations, two SS cell lines (SeAx and HuT-78), and five mononuclear cell
samples (MNC) from healthy donors. Each population, as well as the patients with a particular gene rearrangement, is featured by different colors. The gene
copy number was normalized to 1 million copies of beta 2 microglobulin (B2MG) reference gene. In the MYC expression diagram, information on MYC
amplification (M) and E2A deletions (E) in 8/13 SS patients, published elsewhere by Steininger et al., 2011, positively contributing to MYC expression has
been included. No alterations: (–). In addition, TP53 deletions (T) have been indicated, which might suppress the MYC apoptotic pathway. The level of gene
expression in cell lines that were out of range was given by numbers.
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with published data, in most of the SS samples without MYB
alterations (7/10), increased expression of MYB, as compared
with normal T cells, was observed (mean 9-fold increase;
P¼0.037). Expression of MYC and HSPA8, positively regu-
lated by MYB, was increased in the majority of samples (8/13)
(for MYC 7-fold; P¼0.029, for HSPA8 8-fold P¼0.024).
Increased expression of MYC in samples with low MYB
expression can be explained by MYC amplification and
deletions of MYC-negative regulator E2A, reported previously
in those patients (Steininger et al., 2011). MYC and HSPA8
overexpression was even more evident in nine samples with
MYB overexpression and/or MYC amplification (MYC: 9-fold
increase, P¼ 0.011; HSPA8 10-fold increase, P¼ 0.008). As
HSPA8 is also positively regulated by MYC, this might explain
their very similar pattern of expression. In 4/7 patients with
MYB overexpression, 5-fold increased BCL2 expression was
detected, whereas in all six patients with low MYB expression
the mean BCL2 expression was 2-fold lower than that in
normal T cells, thereby confirming the positive regulations of
BCL2 by MYB in SS cells. Low BCL2 expression in the
majority of cases (9/13) is consistent with previous studies
showing decreased expression of BCL2 in CTCL, and in some
cases might be due BCL2 deletions reported in SS (Mao et al.,
2004). Low expression of PERP was observed in all samples
with 6q23-27 alterations showing monoallelic deletions
(Figure 6). In SeAx with biallelic PERP deletion, no expression
was detected, and in the SS sample 251 with biallelic deletion
very low PERP expression, from the accompanying normal
cells, was observed. As PERP is a p53 apoptosis effector, lack
of its expression may result in nonfunctional p53 signaling
(Davies et al., 2011). Indeed, recently impaired apoptosis
induction after p53 stimulation was reported in SS cells
(Lamprecht et al., 2012; Manfe et al., 2012), which, at least
in some cases, might be due to PERP deletions.
The IL22RA2 gene, encoding a soluble receptor IL-22BP
(Dumoutier et al., 2001), was not expressed in the studied
samples, except for the SeAx cell line, where it was rearranged
with the coiled-coil domain containing 28A gene (CCDC28A)
(Supplementary information 1 online; No 18). Comparative
PCR with two different primer sets for the 50 end (ex1-2) and
for the 30 end (ex2-3) of IL22RA2 detected only the 30 end of
the mRNA, indicating exclusive expression of the rearranged
gene. 50 RACE analysis using reverse nested primers located in
the second exon of IL22RA2 revealed three fusion trans-
cripts with CCDC28A: CCDC28A(ex1,2,3)–IL22RA2(ex2-),
CCDC28A(ex1,3)–IL22RA2(ex2-), and CCDC28A(ex1,2,3)–
IL22RA2(158-bp fragment of in1, ex2-) (Supplementary
information 2 online; GenBank accession numbers
KC819274–6). Recently, out-of-frame CCDC28A(ex1)–
NUP98(ex15) and reciprocal in-frame NUP98(ex13)–
CCDC28(ex2) fusion transcripts have been identified in T-cell
acute lymphoblastic leukemia, with the latter shown to act as
an oncogene (Petit et al., 2012). In our study, all three
identified fusions were out-of-frame, leading to premature
stop codons in the second exon of IL22RA2. The reciprocal
IL22RA2-CCDC28A transcript could not be expressed,
as the 50 part of IL22RA2 and the 30 part of CCDC28A
were deleted.
The t(6;17) fused the AIG1 and the GOSR1 genes in the
same orientation (Figure 4), suggesting a possible expression
of a hybrid mRNA. Reverse transcriptase–PCR revealed two
fusion transcripts being expressed: AIG1(ex1,2)–GOS-
R1(ex2,3,4,5) and AIG1(ex2)–GOSR1(ex2,3,4,5,6,8,9), which
have not been reported to date (Supplementary information 2
online, Genbank accession numbers KC119451-52). Both
variants were out-of-frame, leading to premature stop codons
in the second exon of GOSR1. Whether any of the five
transcriptional variants of the two identified fusions is trans-
lated into a protein (truncated or translated from alternative
start codons) remains to be determined.
In our previous study (Braun et al., 2011), we reported
deletion of the TNFAIP3 gene (A20) in all samples (six patients
and SeAx) showing deletions within the 6q23-27 region. To
our knowledge, interactions between A20 and MYB, IL22RA2,
and other disrupted genes have not been studied yet. Whether
the A20 loss and the disturbed expression of genes affected by
the complex rearrangements might have a synergistic effect in
tumor development remains to be determined.
It is predicted that molecularly based individualized cancer
care, defined as the process of selecting treatment for an
individual patient, based on genetic expression, proteomic
profiles, or deregulated cellular pathways of each individual
patient, is the future of oncology (Mansour and Schwarz,
2008). Yet, extensive research is still needed to identify the
key genes to be targeted. Our study revealed numerous
complex rearrangements associated with the 6q23-27
deletions in SS, disrupting many different genes and thereby
affecting their expression. We did not observe significant
differences in the survival between the patients with and
without 6q alterations. This can be explained by the small
number of analyzed cases, and the presence of other
chromosomal alterations, not analyzed in this study, which
could affect the survival in patients without 6q deletion. This is
in line with the results of Caprini et al, who did not observe
significant differences in the survival for a single alteration
even in a larger cohort of SS (Caprini et al., 2009). Further
studies are needed to unravel the effect of the identified
alterations on the biology of SS cells and their possible role in
the malignant transformation.
MATERIALS AND METHODS
Clinical samples
Thirteen SS blood samples, diagnosed according to the WHO-EORTC
classification for cutaneous lymphomas, and the SeAx SS cell line
were included in the study. All patients were included after giving
written informed consent. The study was approved by the local ethics
committee of the Charite´ (Berlin, Germany), and was conducted in
accordance with the Declaration of Helsinki. All patients were
pretreated before the sample collection with diverse combinations
of therapeutic agents. The clinical information of patients and samples
is summarized in Supplementary information 3 online.
Fine-tiling comparative genomic hybridization
A custom-designed high-density fine-tiling array of 385,000 oligonu-
cleotides, covering the 6q23-27 region, was prepared using the
Maskless Array Synthesizer technology (NimbleGen Systems,
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Reykjavik, Iceland). Results were analyzed using the SignalMap
software (NimbleGen Systems).
Ligation-mediated PCR
DNA losses were analyzed by LM-PCR as described in detail
elsewhere (Przybylski et al., 2005). Briefly, 1mg of high-molecular-
weight DNA was digested with blunt-end restriction enzymes EcoRV,
DraI, PvuII, and StuI (New England Biolabs, Ipswich, MA), and 50mM
of an adaptor was ligated to both ends of the restriction fragments.
The ligation products were subjected to two rounds of PCR with
adaptor-specific and gene-specific primers (Supplementary information
4 online), located at the borders of the deleted regions. LM-PCR
reaction was performed using long-distance Adv Genomic LA Poly-
merase (Clontech, Palo Alto, CA) or Amplus DNA Polymerase (EURx,
Gdansk, Poland) on a DNA Engine Tetrad 2 thermocycler (Bio-Rad,
Foster City, CA). Amplification products were separated by gel electro-
phoresis, and PCR bands differing in size from the germ-line config-
uration were excised from the gel, purified, and directly sequenced. All
rearrangements were confirmed on genomic DNA by regular PCR.
Paired-end NGS
In two samples (SS patient nr 312 and SeAx cell line), paired-end
NGS was performed by Fasteris (Geneva, Switzerland) and LGC
Genomics (Berlin, Germany) on the HiSeq2000 Illumina platform,
according to the manufacturer’s instructions. Briefly, high-molecular-
weight DNA samples were fragmented to about 300bp in the case of
an SS patient and about 900bp in the case of SeAx. Reads of 100bp
were performed from both ends of each fragment. For the patient
sample 312 67.5 Mio paired reads,  6.5Gb of mapped sequence
were obtained. This corresponds to 2.2 sequence coverage and
3.4 rearrangement coverage of the genome. For SeAx 77.3 Mio
paired reads,  7.73Gb of mapped sequence was obtained, corre-
sponding to 2.6 sequence coverage and a high 11.6 rearrange-
ments coverage (due to longer inserts). At least two nonidentical
discordant inserts with 50 and 30 ends, localized in different regions of
the genome, were considered to carry a rearrangement. All rearran-
gements detected by NGS were confirmed by PCR, with primers
located within the discordant reads and classical Sanger sequencing.
SeAx cell line culture and chromosome spreads
SeAx cell line was cultured as described before (Braun et al., 2011).
A large number of metaphase cells were obtained by adding
colcemid. To permit swelling of the nuclei, treatment with
hypotonic salt solution (0.4% KCl) was performed. Cells were fixed
with cold methanol:acetic acid mixture (3:1). Three rounds of
suspension in fixative and centrifugation of cells into a pellet were
used to prepare cells for dropping onto wet and cold slides.
Fluorescence in situ hybridization
Ready-made whole chromosome probes for chromosomes 6 (Plati-
numBright495–green) and 3 (red–PlatinumBright550) (Kreatech Diag-
nostics, Amsterdam, Holland) were used to perform FISH chromo-
some painting. mFISH was performed using the 24Cyte Human
mFISH Probe Kit (MetaSystems GmbH; Altlussheim, Germany). Slides
and probes were prepared using standard procedures. Results were
analyzed under the fluorescence microscope (Axiophot Zeiss).
At the same time, G-banding was performed to assess the band
designation.
RACE
50 RACE was performed using the SMARTer RACE cDNA amplifica-
tion kit (Clontech, Mountain View, CA) and the IL22RA2-specific
primers, 137,524,542exon2If/6 and 137,524,585 exon2If/6, accord-
ing to the manufacturer’s instructions.
Reverse transcriptase–PCR and comparative PCR
RNA extraction and reverse transcription were performed as pre-
viously described (Braun et al., 2011). Reverse transcriptase–PCR was
performed to confirm the AIG1–GOSR1 and CCDC28A–IL22RA2
fusions at the mRNA level in SeAx, whereas comparative PCR with
two sets of primers was used to compare the relative levels of mRNA
variants (Supplementary information 4 online).
Real-time quantitative PCR
RQ-PCR was performed using the ICycler thermocycler (Bio-Rad).
The following genes were analyzed using TaqMan Gene Expression
assays: PERP (Hs00953483_g1), IL22RA2 (Hs00364814_ml),
BCL2 (Hs00608023_m1), MYC (Hs00153408_m1), HSPA8
(Hs01683591_g1), and MYB (Hs00920554_m1, exons 1–2;
Hs00193527_m1, exons 14–15) (Applied Biosystems, Foster City,
CA). B2M (Hs00984230_m1) was used as a reference gene. The
analysis was performed for 13 SS patients (six with rearrangements in
the 6q23-27 and seven without rearrangements), and 5 ficoll-purified
mononuclear cells from healthy donors were used as controls. All
samples were assayed in duplicate. Statistical analysis of the differ-
ences in the gene expression was performed using two-tailed
Student’s t-test for unpaired data.
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